Monitor for future 8-Ks or press releases disclosing actual revenue or unit sales from the LIBERTY system. The GEST conference (May 14-17) could be a catalyst for further commercial announcements. The lack of any financial data makes this a low-conviction event.
Price Chart
Executive Summary
Microbot Medical announced initial commercial adoption of its LIBERTY Endovascular Robotic System following its full market release at the SIR annual meeting, including wins at two clinical trial sites. The company also plans to attend the GEST conference in May 2026 to expand its commercial footprint. No financial figures or guidance were provided.
Key Facts
- LIBERTY Endovascular Robotic System has been adopted by multiple accounts in key sales territories since full market release
- Two accounts that participated in the ACCESS-PVI pivotal clinical trial have adopted the system
- Company will attend the GEST conference in New York City from May 14-17, 2026
- Alon Tamir recently appointed as Vice President of Sales, EMEA to lead international commercialization
- No financial data, revenue figures, or unit sales numbers were disclosed
Financial Impact
No financial figures disclosed in the filing
Risk Factors
- No revenue or financial metrics disclosed — commercial adoption may not translate to material revenue
- Early-stage commercial launch with limited account wins; scalability unproven
- Forward-looking statements about momentum and expansion are not guaranteed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-021231 |
| Exhibit: ex99-1.htm | 0001493152-26-021231 |
| Document: 0001493152-26-021231-index-headers.html | 0001493152-26-021231 |
| Document: 0001493152-26-021231-index.html | 0001493152-26-021231 |
| Document: 0001493152-26-021231.txt | 0001493152-26-021231 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.9739 $0.9417 | ▼ −3.31% | ▼ −4.02% | $0.9417 (−3.31%) |
Oct 20, 2026 6d ago | 8-K | $0.9475 $0.9401 | ▼ −0.78% | ▼ −1.31% | $0.9417 (−0.61%) |
Oct 6, 2026 20d ago | 8-K | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9417 (−11.99%) |
Oct 6, 2026 20d ago | Press Release | $1.07 $1.12 | ▲ +4.67% | ▲ +4.91% | $0.9417 (−11.99%) |
Sep 28, 2026 28d ago | 8-K | $1.25 $1.25 | ▼ −0.40% | ▼ −0.22% | $0.9417 (−24.66%) |
Aug 11, 2026 10w ago | 8-K | $1.68 $1.74 | ▲ +3.27% | ▲ +3.02% | $0.9417 (−43.95%) |
Jul 21, 2026 13w ago | 8-K | $1.80 $1.77 | ▼ −1.67% | ▼ −1.55% | $0.9417 (−47.68%) |
Jul 7, 2026 15w ago | 8-K | $1.90 $1.87 | ▼ −1.58% | ▼ −1.27% | $0.9417 (−50.44%) |
Jun 30, 2026 16w ago | 8-K | $1.95 $1.91 | ▼ −2.05% | ▼ −1.92% | $0.9417 (−51.71%) |
Jun 16, 2026 18w ago | 8-K | $1.82 $1.88 | ▲ +3.30% | ▲ +4.55% | $0.9417 (−48.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers